199 related articles for article (PubMed ID: 37419078)
21. Comparison of breast cancer HER-2 receptor testing with immunohistochemistry and in situ hybridization.
Shanmugalingam A; Hitos K; Pathmanathan N; Edirimmane S; Hughes TM; Ngui NK
Breast Cancer Res Treat; 2023 Feb; 198(1):143-148. PubMed ID: 36604351
[TBL] [Abstract][Full Text] [Related]
22. Can AI-assisted microscope facilitate breast HER2 interpretation? A multi-institutional ring study.
Yue M; Zhang J; Wang X; Yan K; Cai L; Tian K; Niu S; Han X; Yu Y; Huang J; Han D; Yao J; Liu Y
Virchows Arch; 2021 Sep; 479(3):443-449. PubMed ID: 34279719
[TBL] [Abstract][Full Text] [Related]
23. Digital image analysis and assisted reading of the HER2 score display reduced concordance: pitfalls in the categorisation of HER2-low breast cancer.
Sode M; Thagaard J; Eriksen JO; Laenkholm AV
Histopathology; 2023 May; 82(6):912-924. PubMed ID: 36737248
[TBL] [Abstract][Full Text] [Related]
24. Concordance in Breast Cancer Grading by Artificial Intelligence on Whole Slide Images Compares With a Multi-Institutional Cohort of Breast Pathologists.
Mantrala S; Ginter PS; Mitkari A; Joshi S; Prabhala H; Ramachandra V; Kini L; Idress R; D'Alfonso TM; Fineberg S; Jaffer S; Sattar AK; Chagpar AB; Wilson P; Singh K; Harigopal M; Koka D
Arch Pathol Lab Med; 2022 Nov; 146(11):1369-1377. PubMed ID: 35271701
[TBL] [Abstract][Full Text] [Related]
25. A retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas: impact of 2007 American Society of Clinical Oncology/College of American Pathologists criteria.
Schalper KA; Kumar S; Hui P; Rimm DL; Gershkovich P
Arch Pathol Lab Med; 2014 Feb; 138(2):213-9. PubMed ID: 24164555
[TBL] [Abstract][Full Text] [Related]
26. Dual-color dual-hapten in situ hybridization (D-DISH) - Comparison with fluorescence in situ hybridization (FISH) for HER2/neu testing in breast cancer.
Gajaria PK; Tambe S; Pai T; Patil A; Desai SB; Shet TM
Indian J Pathol Microbiol; 2020; 63(2):194-199. PubMed ID: 32317514
[TBL] [Abstract][Full Text] [Related]
27. Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study.
Bilous M; Ades C; Armes J; Bishop J; Brown R; Cooke B; Cummings M; Farshid G; Field A; Morey A; McKenzie P; Raymond W; Robbins P; Tan L
Breast; 2003 Apr; 12(2):92-8. PubMed ID: 14659337
[TBL] [Abstract][Full Text] [Related]
28. Use of Web-based training for quality improvement between a field immunohistochemistry laboratory in Nigeria and its United States-based partner institution.
Oluwasola AO; Malaka D; Khramtsov AI; Ikpatt OF; Odetunde A; Adeyanju OO; Sveen WE; Falusi AG; Huo D; Olopade OI
Ann Diagn Pathol; 2013 Dec; 17(6):526-30. PubMed ID: 24095629
[TBL] [Abstract][Full Text] [Related]
29. Low interobserver agreement among subspecialised breast pathologists in evaluating HER2-low breast cancer.
Turashvili G; Gao Y; Ai DA; Ewaz AM; Gjeorgjievski SG; Wang Q; Nguyen TTA; Zhang C; Li X
J Clin Pathol; 2023 Sep; ():. PubMed ID: 37714693
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of analytical accuracy of HER2 status in patients with breast cancer: Comparison of HER2 GPA with HER2 IHC and HER2 FISH.
Jensen SG; Thomas PE; Christensen IJ; Balslev E; Hansen A; Høgdall E
APMIS; 2020 Nov; 128(11):573-582. PubMed ID: 32860265
[TBL] [Abstract][Full Text] [Related]
31. Inter- and Intra-Observer Agreement of PD-L1 SP142 Scoring in Breast Carcinoma-A Large Multi-Institutional International Study.
Zaakouk M; Van Bockstal M; Galant C; Callagy G; Provenzano E; Hunt R; D'Arrigo C; Badr NM; O'Sullivan B; Starczynski J; Tanchel B; Mir Y; Lewis P; Shaaban AM
Cancers (Basel); 2023 Feb; 15(5):. PubMed ID: 36900303
[TBL] [Abstract][Full Text] [Related]
32. HER2 in gastric cancer: comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays.
Abrahão-Machado LF; Jácome AA; Wohnrath DR; dos Santos JS; Carneseca EC; Fregnani JH; Scapulatempo-Neto C
World J Gastroenterol; 2013 Oct; 19(38):6438-46. PubMed ID: 24151362
[TBL] [Abstract][Full Text] [Related]
33. [Intralaboratory reproducibility of HER2 testing in breast cancer by immunohistochemistry and comparison of results obtained by different assays].
Yang Y; Wei B; Zhang Z; Tang Y; Fu J; Liao DY; Li FY; Bu H
Zhonghua Bing Li Xue Za Zhi; 2009 Jan; 38(1):29-34. PubMed ID: 19489222
[TBL] [Abstract][Full Text] [Related]
34. Breast carcinomas with low amplified/equivocal HER2 by Ish: potential supporting role of multiplex ligation-dependent probe amplification.
Ercolani C; Marchiò C; Di Benedetto A; Fabi A; Perracchio L; Vici P; Sperati F; Buglioni S; Arena V; Pescarmona E; Sapino A; Terrenato I; Mottolese M
J Exp Clin Cancer Res; 2017 Oct; 36(1):143. PubMed ID: 29029640
[TBL] [Abstract][Full Text] [Related]
35. Evaluating Low HER2 Status in Invasive Breast Carcinoma via HER2 Immunohistochemistry, with HER2 FISH Correlation: A Cohort of 112 Patients.
Ardor GD; Komforti MK; Hanna H; Ibanoglu O; Lochala A; Nassar A
Breast J; 2023; 2023():9725647. PubMed ID: 37664543
[TBL] [Abstract][Full Text] [Related]
36. HER2 testing by immunohistochemistry in breast cancer: A multicenter proficiency ring study.
Md Pauzi SH; Masir N; Yahaya A; Mohammed F; Tizen Laim NMS; Mustangin M; Aizudin AN; Talib A; Teoh KH; Karim N; Oy-Leng JW; Rajadurai P
Indian J Pathol Microbiol; 2021; 64(4):677-682. PubMed ID: 34673585
[TBL] [Abstract][Full Text] [Related]
37. Breast MRI background parenchymal enhancement as an imaging bridge to molecular cancer sub-type.
Dilorenzo G; Telegrafo M; La Forgia D; Stabile Ianora AA; Moschetta M
Eur J Radiol; 2019 Apr; 113():148-152. PubMed ID: 30927939
[TBL] [Abstract][Full Text] [Related]
38. New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers.
Tchrakian N; Flanagan L; Harford J; Gannon JM; Quinn CM
Virchows Arch; 2016 Feb; 468(2):207-11. PubMed ID: 26521061
[TBL] [Abstract][Full Text] [Related]
39. High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system.
Gown AM; Goldstein LC; Barry TS; Kussick SJ; Kandalaft PL; Kim PM; Tse CC
Mod Pathol; 2008 Oct; 21(10):1271-7. PubMed ID: 18487992
[TBL] [Abstract][Full Text] [Related]
40. Comparison of Dako HercepTest and Ventana PATHWAY Anti-HER2 (4B5) Tests and Their Correlation With Fluorescent In Situ Hybridization in Breast Carcinoma.
Lucas E; Jabbar SB; Molberg K; Fang Y; Xie XJ; Blacketer S; Sahoo S
Appl Immunohistochem Mol Morphol; 2019 Jul; 27(6):403-409. PubMed ID: 31233398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
